Balemans W. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 2005;36(6):943-7.
Balemans W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10(5):537-43.
Balemans W. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002;39(2):91-7.
Beighton P. The syndromic status of sclerosteosis and van Buchem disease. Clin Genet 1984;25(2):175-81.
Bezooijen RL. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005;16(3):319-27.
Boyden LM. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513-21.
Brunkow ME. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68(3):577-89.
Gaur T. Canonical WNT signaling promotes osteogenesis by directly stimulating RUNX2 gene expression. J Biol Chem 2005.
Gong Y. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-23.
Hamersma H. The natural history of sclerosteosis. Clin Genet 2003;63(3):192-7.
Johnson ML. LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res 2004;19(11):1749-57.
Keller H. SOST is a target gene for PTH in bone. Bone 2005;37(2):148-58.
Kulkarni NH. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 2005;95(6):1178-90.
Kusu N. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003;278(26):24113-7.
Levasseur R. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 2005;72(3):207-14.
Li X. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280(20):19883-7.
Little RD. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70:11-9.
Loots GG. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005;15(7):928-35.
Moon RT. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5(9):691-701.
Nusse R. Developmental biology. Making head or tail of Dickkopf. Nature 2001;411:255-6.
Nusse R. Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface. Development 2003;130:5297-305.
Rawadi G. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003;18:1842-53.
Ross SE. Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Mol Cell Biol 2002;22:5989-99.
Ross SE. Inhibition of adipogenesis by Wnt signaling. Science 2000;289:950-3.
Semenov M. SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor. J Biol Chem 2005;280(29):26770-5.
Sevetson B. Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J Biol Chem 2004;279(14):13849-58.
Shao JS. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005;115(5):1210-20.
Staehling-Hampton K. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 2002;110(2):144-52.
Sutherland MK. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004;35(4):828-35.
Sutherland MK. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004;35(2):448-54.
Tian E. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94.
Uitterlinden AG. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet 2004;75(6):1032-45.
van Bezooijen RL. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199(6):805-14.
Van Wesenbeeck L. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003;72:763-71.
Vestergaard P. Reduced Relative Risk of Fractures Among Users of Lithium. Calcif Tissue Int 2005.
Wergedal JE. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 2003;88(12):5778-83.
Willert K. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003;423:448-52.
Winkler DG. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. Embo J 2003;22(23):6267-76.
Winkler DG. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 2005;280(4):2498-502.
Winkler DG. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 2004;279(35):36293-8.
Updated 8/5/05